---
document_datetime: 2025-12-02 05:06:49
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/lacosamide-adroiq.html
document_name: lacosamide-adroiq.html
version: success
processing_time: 0.1242521
conversion_datetime: 2025-12-24 16:35:57.79613
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Lacosamide Adroiq

[RSS](/en/individual-human-medicine.xml/67677)

##### Authorised

This medicine is authorised for use in the European Union

lacosamide Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Lacosamide Adroiq](#news-on)
- [Product information - with tracked changes](#product-information-with-tracked-changes-79586)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Lacosamide Adroiq is a medicine used on its own or as an add-on to other epilepsy medicines in the treatment of partial-onset seizures (epileptic fits starting in one specific part of the brain) with or without secondary generalisation (where the abnormal electrical activity spreads through the brain) in patients with epilepsy aged 2 years and older.

Lacosamide Adroiq can also be used as add-on to other epilepsy medicines in the treatment of primary generalised tonic-clonic seizures (major fits, including loss of consciousness) in patients from 4 years of age with idiopathic generalised epilepsy (the type of epilepsy that is thought to have a genetic cause).

Lacosamide Adroiq is a 'generic medicine'. This means that Lacosamide Adroiq contains the same active substance and works in the same way as a 'reference medicine' already authorised in the EU. The reference medicine for Lacosamide Adroiq is Vimpat. For more information on generic medicines, see the question-and-answer document [here](https://www.ema.europa.eu/en/documents/medicine-qa/questions-answers-generic-medicines_en.pdf) .

Lacosamide Adroiq contains the active substance lacosamide.

Expand section

Collapse section

## How is Lacosamide Adroiq used?

Lacosamide Adroiq is available as a solution for infusion (drip) into a vein and is given twice a day.

The medicine can only be obtained with a prescription.

For more information about using Lacosamide Adroiq, see the package leaflet or contact your doctor or pharmacist.

## How does Lacosamide Adroiq work?

The active substance in Lacosamide Adroiq, lacosamide, is an epilepsy medicine. Epilepsy is caused by abnormal electrical activity in the brain. The exact way in which lacosamide works is unclear but it seems to reduce the activity of sodium channels (pores on the surface of nerve cells) that allow electrical impulses to be transmitted between nerve cells. This action may prevent abnormal electrical activity in the brain, reducing the chance of an epileptic fit.

## How has Lacosamide Adroiq been studied?

Studies on the benefits and risks of the active substance in the authorised uses have already been carried out with the reference medicine, Vimpat, and do not need to be repeated for Lacosamide Adroiq.

As for every medicine, the company provided studies on the quality of Lacosamide Adroiq. There was no need for 'bioequivalence' studies to investigate whether Lacosamide Adroiq is absorbed similarly to the reference medicine to produce the same level of the active substance in the blood. This is because Lacosamide Adroiq is given by infusion into a vein, so the active substance is delivered straight into the bloodstream.

## What are the benefits and risks of Lacosamide Adroiq?

Because Lacosamide Adroiq is a generic medicine, its benefits and risks are taken as being the same as the reference medicine's.

For the list of side effects and restrictions with Lacosamide Adroiq, see the package leaflet.

## Why is Lacosamide Adroiq authorised in the EU?

The European Medicines Agency concluded that, in accordance with EU requirements, Lacosamide Adroiq has been shown to be comparable to Vimpat. Therefore, the Agency's view was that, as for Vimpat, the benefits of Lacosamide Adroiq outweigh the identified risks and it can be authorised for use in the EU.

## What measures are being taken to ensure the safe and effective use of Lacosamide Adroiq?

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Lacosamide Adroiq have been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Lacosamide Adroiq are continuously monitored. Suspected side effects reported with Lacosamide Adroiq are carefully evaluated and any necessary action taken to protect patients.

## Other information about Lacosamide Adroiq

Lacosamide Adroiq received a marketing authorisation valid throughout the EU on 31 May 2023.

Lacosamide Adroiq : EPAR - Medicine Overview

Reference Number: EMA/162596/2023

English (EN) (143.42 KB - PDF)

**First published:** 05/06/2023

[View](/en/documents/overview/lacosamide-adroiq-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-883)

български (BG) (166.42 KB - PDF)

**First published:**

05/06/2023

[View](/bg/documents/overview/lacosamide-adroiq-epar-medicine-overview_bg.pdf)

español (ES) (143.92 KB - PDF)

**First published:**

05/06/2023

[View](/es/documents/overview/lacosamide-adroiq-epar-medicine-overview_es.pdf)

čeština (CS) (164.29 KB - PDF)

**First published:**

05/06/2023

[View](/cs/documents/overview/lacosamide-adroiq-epar-medicine-overview_cs.pdf)

dansk (DA) (143.11 KB - PDF)

**First published:**

05/06/2023

[View](/da/documents/overview/lacosamide-adroiq-epar-medicine-overview_da.pdf)

Deutsch (DE) (146.93 KB - PDF)

**First published:**

05/06/2023

[View](/de/documents/overview/lacosamide-adroiq-epar-medicine-overview_de.pdf)

eesti keel (ET) (132.43 KB - PDF)

**First published:**

05/06/2023

[View](/et/documents/overview/lacosamide-adroiq-epar-medicine-overview_et.pdf)

ελληνικά (EL) (166.12 KB - PDF)

**First published:**

05/06/2023

[View](/el/documents/overview/lacosamide-adroiq-epar-medicine-overview_el.pdf)

français (FR) (145.12 KB - PDF)

**First published:**

05/06/2023

[View](/fr/documents/overview/lacosamide-adroiq-epar-medicine-overview_fr.pdf)

hrvatski (HR) (160.34 KB - PDF)

**First published:**

05/06/2023

[View](/hr/documents/overview/lacosamide-adroiq-epar-medicine-overview_hr.pdf)

italiano (IT) (143.14 KB - PDF)

**First published:**

05/06/2023

[View](/it/documents/overview/lacosamide-adroiq-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (173.17 KB - PDF)

**First published:**

05/06/2023

[View](/lv/documents/overview/lacosamide-adroiq-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (163.63 KB - PDF)

**First published:**

05/06/2023

[View](/lt/documents/overview/lacosamide-adroiq-epar-medicine-overview_lt.pdf)

magyar (HU) (164.44 KB - PDF)

**First published:**

05/06/2023

[View](/hu/documents/overview/lacosamide-adroiq-epar-medicine-overview_hu.pdf)

Malti (MT) (166.97 KB - PDF)

**First published:**

05/06/2023

[View](/mt/documents/overview/lacosamide-adroiq-epar-medicine-overview_mt.pdf)

Nederlands (NL) (144.35 KB - PDF)

**First published:**

05/06/2023

[View](/nl/documents/overview/lacosamide-adroiq-epar-medicine-overview_nl.pdf)

polski (PL) (166.84 KB - PDF)

**First published:**

05/06/2023

[View](/pl/documents/overview/lacosamide-adroiq-epar-medicine-overview_pl.pdf)

português (PT) (144.65 KB - PDF)

**First published:**

05/06/2023

[View](/pt/documents/overview/lacosamide-adroiq-epar-medicine-overview_pt.pdf)

română (RO) (161.34 KB - PDF)

**First published:**

05/06/2023

[View](/ro/documents/overview/lacosamide-adroiq-epar-medicine-overview_ro.pdf)

slovenčina (SK) (164.11 KB - PDF)

**First published:**

05/06/2023

[View](/sk/documents/overview/lacosamide-adroiq-epar-medicine-overview_sk.pdf)

slovenščina (SL) (162.29 KB - PDF)

**First published:**

05/06/2023

[View](/sl/documents/overview/lacosamide-adroiq-epar-medicine-overview_sl.pdf)

Suomi (FI) (142.12 KB - PDF)

**First published:**

05/06/2023

[View](/fi/documents/overview/lacosamide-adroiq-epar-medicine-overview_fi.pdf)

svenska (SV) (142.27 KB - PDF)

**First published:**

05/06/2023

[View](/sv/documents/overview/lacosamide-adroiq-epar-medicine-overview_sv.pdf)

Lacosamide Adroiq : EPAR - Risk management plan summary

English (EN) (196.85 KB - PDF)

**First published:** 05/06/2023

[View](/en/documents/rmp-summary/lacosamide-adroiq-epar-risk-management-plan-summary_en.pdf)

## Product information

Lacosamide Adroiq : EPAR - Product Information

English (EN) (586.34 KB - PDF)

**First published:** 05/06/2023

**Last updated:** 25/09/2025

[View](/en/documents/product-information/lacosamide-adroiq-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-448)

български (BG) (423.66 KB - PDF)

**First published:**

05/06/2023

**Last updated:**

25/09/2025

[View](/bg/documents/product-information/lacosamide-adroiq-epar-product-information_bg.pdf)

español (ES) (541.01 KB - PDF)

**First published:**

05/06/2023

**Last updated:**

25/09/2025

[View](/es/documents/product-information/lacosamide-adroiq-epar-product-information_es.pdf)

čeština (CS) (413.52 KB - PDF)

**First published:**

05/06/2023

**Last updated:**

25/09/2025

[View](/cs/documents/product-information/lacosamide-adroiq-epar-product-information_cs.pdf)

dansk (DA) (516.38 KB - PDF)

**First published:**

05/06/2023

**Last updated:**

25/09/2025

[View](/da/documents/product-information/lacosamide-adroiq-epar-product-information_da.pdf)

Deutsch (DE) (560.93 KB - PDF)

**First published:**

05/06/2023

**Last updated:**

25/09/2025

[View](/de/documents/product-information/lacosamide-adroiq-epar-product-information_de.pdf)

eesti keel (ET) (509.66 KB - PDF)

**First published:**

05/06/2023

**Last updated:**

25/09/2025

[View](/et/documents/product-information/lacosamide-adroiq-epar-product-information_et.pdf)

ελληνικά (EL) (637.55 KB - PDF)

**First published:**

05/06/2023

**Last updated:**

25/09/2025

[View](/el/documents/product-information/lacosamide-adroiq-epar-product-information_el.pdf)

français (FR) (567.29 KB - PDF)

**First published:**

05/06/2023

**Last updated:**

25/09/2025

[View](/fr/documents/product-information/lacosamide-adroiq-epar-product-information_fr.pdf)

hrvatski (HR) (614.29 KB - PDF)

**First published:**

05/06/2023

**Last updated:**

25/09/2025

[View](/hr/documents/product-information/lacosamide-adroiq-epar-product-information_hr.pdf)

íslenska (IS) (548.61 KB - PDF)

**First published:**

05/06/2023

**Last updated:**

25/09/2025

[View](/is/documents/product-information/lacosamide-adroiq-epar-product-information_is.pdf)

italiano (IT) (559.07 KB - PDF)

**First published:**

05/06/2023

**Last updated:**

25/09/2025

[View](/it/documents/product-information/lacosamide-adroiq-epar-product-information_it.pdf)

latviešu valoda (LV) (621.34 KB - PDF)

**First published:**

05/06/2023

**Last updated:**

25/09/2025

[View](/lv/documents/product-information/lacosamide-adroiq-epar-product-information_lv.pdf)

lietuvių kalba (LT) (612.54 KB - PDF)

**First published:**

05/06/2023

**Last updated:**

25/09/2025

[View](/lt/documents/product-information/lacosamide-adroiq-epar-product-information_lt.pdf)

magyar (HU) (634.24 KB - PDF)

**First published:**

05/06/2023

**Last updated:**

25/09/2025

[View](/hu/documents/product-information/lacosamide-adroiq-epar-product-information_hu.pdf)

Malti (MT) (693.9 KB - PDF)

**First published:**

05/06/2023

**Last updated:**

25/09/2025

[View](/mt/documents/product-information/lacosamide-adroiq-epar-product-information_mt.pdf)

Nederlands (NL) (575.36 KB - PDF)

**First published:**

05/06/2023

**Last updated:**

25/09/2025

[View](/nl/documents/product-information/lacosamide-adroiq-epar-product-information_nl.pdf)

norsk (NO) (529.21 KB - PDF)

**First published:**

05/06/2023

**Last updated:**

25/09/2025

[View](/no/documents/product-information/lacosamide-adroiq-epar-product-information_no.pdf)

polski (PL) (726.11 KB - PDF)

**First published:**

05/06/2023

**Last updated:**

25/09/2025

[View](/pl/documents/product-information/lacosamide-adroiq-epar-product-information_pl.pdf)

português (PT) (643.81 KB - PDF)

**First published:**

05/06/2023

**Last updated:**

25/09/2025

[View](/pt/documents/product-information/lacosamide-adroiq-epar-product-information_pt.pdf)

română (RO) (694.49 KB - PDF)

**First published:**

05/06/2023

**Last updated:**

25/09/2025

[View](/ro/documents/product-information/lacosamide-adroiq-epar-product-information_ro.pdf)

slovenčina (SK) (744.96 KB - PDF)

**First published:**

05/06/2023

**Last updated:**

25/09/2025

[View](/sk/documents/product-information/lacosamide-adroiq-epar-product-information_sk.pdf)

slovenščina (SL) (611.14 KB - PDF)

**First published:**

05/06/2023

**Last updated:**

25/09/2025

[View](/sl/documents/product-information/lacosamide-adroiq-epar-product-information_sl.pdf)

Suomi (FI) (520.74 KB - PDF)

**First published:**

05/06/2023

**Last updated:**

25/09/2025

[View](/fi/documents/product-information/lacosamide-adroiq-epar-product-information_fi.pdf)

svenska (SV) (530.98 KB - PDF)

**First published:**

05/06/2023

**Last updated:**

25/09/2025

[View](/sv/documents/product-information/lacosamide-adroiq-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** VR/0000297357 23/09/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Lacosamide Adroiq : EPAR - All authorised presentations

English (EN) (36.03 KB - PDF)

**First published:** 05/06/2023

**Last updated:** 13/10/2023

[View](/en/documents/all-authorised-presentations/lacosamide-adroiq-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-574)

български (BG) (44.6 KB - PDF)

**First published:**

05/06/2023

**Last updated:**

13/10/2023

[View](/bg/documents/all-authorised-presentations/lacosamide-adroiq-epar-all-authorised-presentations_bg.pdf)

español (ES) (37.42 KB - PDF)

**First published:**

05/06/2023

**Last updated:**

13/10/2023

[View](/es/documents/all-authorised-presentations/lacosamide-adroiq-epar-all-authorised-presentations_es.pdf)

čeština (CS) (42 KB - PDF)

**First published:**

05/06/2023

**Last updated:**

13/10/2023

[View](/cs/documents/all-authorised-presentations/lacosamide-adroiq-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (40.04 KB - PDF)

**First published:**

05/06/2023

**Last updated:**

13/10/2023

[View](/da/documents/all-authorised-presentations/lacosamide-adroiq-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (39.15 KB - PDF)

**First published:**

05/06/2023

**Last updated:**

13/10/2023

[View](/de/documents/all-authorised-presentations/lacosamide-adroiq-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (35 KB - PDF)

**First published:**

05/06/2023

**Last updated:**

13/10/2023

[View](/et/documents/all-authorised-presentations/lacosamide-adroiq-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (41.46 KB - PDF)

**First published:**

05/06/2023

**Last updated:**

13/10/2023

[View](/el/documents/all-authorised-presentations/lacosamide-adroiq-epar-all-authorised-presentations_el.pdf)

français (FR) (37.61 KB - PDF)

**First published:**

05/06/2023

**Last updated:**

13/10/2023

[View](/fr/documents/all-authorised-presentations/lacosamide-adroiq-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (39.9 KB - PDF)

**First published:**

05/06/2023

**Last updated:**

13/10/2023

[View](/hr/documents/all-authorised-presentations/lacosamide-adroiq-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (39.94 KB - PDF)

**First published:**

05/06/2023

**Last updated:**

13/10/2023

[View](/is/documents/all-authorised-presentations/lacosamide-adroiq-epar-all-authorised-presentations_is.pdf)

italiano (IT) (79.77 KB - PDF)

**First published:**

05/06/2023

**Last updated:**

13/10/2023

[View](/it/documents/all-authorised-presentations/lacosamide-adroiq-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (41.43 KB - PDF)

**First published:**

05/06/2023

**Last updated:**

13/10/2023

[View](/lv/documents/all-authorised-presentations/lacosamide-adroiq-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (40.81 KB - PDF)

**First published:**

05/06/2023

**Last updated:**

13/10/2023

[View](/lt/documents/all-authorised-presentations/lacosamide-adroiq-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (39.93 KB - PDF)

**First published:**

05/06/2023

**Last updated:**

13/10/2023

[View](/hu/documents/all-authorised-presentations/lacosamide-adroiq-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (103.29 KB - PDF)

**First published:**

05/06/2023

**Last updated:**

13/10/2023

[View](/mt/documents/all-authorised-presentations/lacosamide-adroiq-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (36.52 KB - PDF)

**First published:**

05/06/2023

**Last updated:**

13/10/2023

[View](/nl/documents/all-authorised-presentations/lacosamide-adroiq-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (47.31 KB - PDF)

**First published:**

05/06/2023

**Last updated:**

13/10/2023

[View](/no/documents/all-authorised-presentations/lacosamide-adroiq-epar-all-authorised-presentations_no.pdf)

polski (PL) (42.43 KB - PDF)

**First published:**

05/06/2023

**Last updated:**

13/10/2023

[View](/pl/documents/all-authorised-presentations/lacosamide-adroiq-epar-all-authorised-presentations_pl.pdf)

português (PT) (38.72 KB - PDF)

**First published:**

05/06/2023

**Last updated:**

13/10/2023

[View](/pt/documents/all-authorised-presentations/lacosamide-adroiq-epar-all-authorised-presentations_pt.pdf)

română (RO) (39.76 KB - PDF)

**First published:**

05/06/2023

**Last updated:**

13/10/2023

[View](/ro/documents/all-authorised-presentations/lacosamide-adroiq-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (42.63 KB - PDF)

**First published:**

05/06/2023

**Last updated:**

13/10/2023

[View](/sk/documents/all-authorised-presentations/lacosamide-adroiq-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (37.95 KB - PDF)

**First published:**

05/06/2023

**Last updated:**

13/10/2023

[View](/sl/documents/all-authorised-presentations/lacosamide-adroiq-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (35.45 KB - PDF)

**First published:**

05/06/2023

**Last updated:**

13/10/2023

[View](/fi/documents/all-authorised-presentations/lacosamide-adroiq-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (37.17 KB - PDF)

**First published:**

05/06/2023

**Last updated:**

13/10/2023

[View](/sv/documents/all-authorised-presentations/lacosamide-adroiq-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Lacosamide Adroiq Active substance lacosamide International non-proprietary name (INN) or common name lacosamide Therapeutic area (MeSH) Epilepsy Anatomical therapeutic chemical (ATC) code N03AX18

### Pharmacotherapeutic group

Antiepileptics

### Therapeutic indication

Lacosamide Adroiq is indicated as monotherapy in the treatment of partial-onset seizures with or without secondary generalisation in adults, adolescents and children from 2 years of age with epilepsy.

Lacosamide Adroiq is indicated as adjunctive therapy

- in the treatment of partial-onset seizures with or without secondary generalisation in adults, adolescents and children from 2 years of age with epilepsy.
- in the treatment of primary generalised tonic-clonic seizures in adults, adolescents and children from 4 years of age with idiopathic generalised epilepsy.

## Authorisation details

EMA product number EMEA/H/C/006047

Generic

This is a generic medicine, which is developed to be the same as a medicine that has already been authorised, called the reference medicine. A generic medicine contains the same active substance(s) as the reference medicine, and is used at the same dose(s) to treat the same disease(s). For more information, see [Generic and hybrid medicines](/node/69107) .

Marketing authorisation holder

Extrovis EU Ltd

Raktarvarosi Ut 9 Torokbalint 2045 Hungary

Opinion adopted 30/03/2023 Marketing authorisation issued 31/05/2023 Revision 6

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Lacosamide Adroiq : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (248.14 KB - PDF)

**First published:** 25/09/2025

[View](/en/documents/procedural-steps-after/lacosamide-adroiq-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Lacosamide Adroiq : EPAR - Procedural steps taken and scientific information after authorisation (archive)

English (EN) (109.12 KB - PDF)

**First published:** 14/09/2023

**Last updated:** 25/09/2025

[View](/en/documents/procedural-steps-after/lacosamide-adroiq-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf)

## Initial marketing authorisation documents

Lacosamide Adroiq : EPAR - Public Assessment Report

Adopted

Reference Number: EMA/216528/2023

English (EN) (388.16 KB - PDF)

**First published:** 05/06/2023

[View](/en/documents/assessment-report/lacosamide-adroiq-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Lacosamide Adroiq

Adopted

Reference Number: EMA/CHMP/126756/2023

English (EN) (154.9 KB - PDF)

**First published:** 31/03/2023

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-lacosamide-adroiq_en.pdf)

#### News on Lacosamide Adroiq

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 27 - 30 March 2023](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-27-30-march-2023) 31/03/2023

#### Product information - with tracked changes

The approved product information for this medicine is available below showing the changes since the previous procedure affecting the product information. The same document without tracked changes is above under 'Product information'.

Lacosamide Adroiq : EPAR - Product information - tracked changes

English (EN) (179.56 KB - DOCX)

**First published:** 25/09/2025

[View](/en/documents/product-information-tracked-changes/lacosamide-adroiq-epar-product-information-tracked-changes_en.docx)

[Other languages (24)](#file-language-dropdown-612)

български (BG) (166.07 KB - DOCX)

**First published:**

25/09/2025

[View](/bg/documents/product-information-tracked-changes/lacosamide-adroiq-epar-product-information-tracked-changes_bg.docx)

español (ES) (147.32 KB - DOCX)

**First published:**

25/09/2025

[View](/es/documents/product-information-tracked-changes/lacosamide-adroiq-epar-product-information-tracked-changes_es.docx)

čeština (CS) (157.3 KB - DOCX)

**First published:**

25/09/2025

[View](/cs/documents/product-information-tracked-changes/lacosamide-adroiq-epar-product-information-tracked-changes_cs.docx)

dansk (DA) (174.56 KB - DOCX)

**First published:**

25/09/2025

[View](/da/documents/product-information-tracked-changes/lacosamide-adroiq-epar-product-information-tracked-changes_da.docx)

Deutsch (DE) (151.16 KB - DOCX)

**First published:**

25/09/2025

[View](/de/documents/product-information-tracked-changes/lacosamide-adroiq-epar-product-information-tracked-changes_de.docx)

eesti keel (ET) (140.84 KB - DOCX)

**First published:**

25/09/2025

[View](/et/documents/product-information-tracked-changes/lacosamide-adroiq-epar-product-information-tracked-changes_et.docx)

ελληνικά (EL) (151.9 KB - DOCX)

**First published:**

25/09/2025

[View](/el/documents/product-information-tracked-changes/lacosamide-adroiq-epar-product-information-tracked-changes_el.docx)

français (FR) (143.69 KB - DOCX)

**First published:**

25/09/2025

[View](/fr/documents/product-information-tracked-changes/lacosamide-adroiq-epar-product-information-tracked-changes_fr.docx)

hrvatski (HR) (154.78 KB - DOCX)

**First published:**

25/09/2025

[View](/hr/documents/product-information-tracked-changes/lacosamide-adroiq-epar-product-information-tracked-changes_hr.docx)

íslenska (IS) (144.01 KB - DOCX)

**First published:**

25/09/2025

[View](/is/documents/product-information-tracked-changes/lacosamide-adroiq-epar-product-information-tracked-changes_is.docx)

italiano (IT) (126.81 KB - DOCX)

**First published:**

25/09/2025

[View](/it/documents/product-information-tracked-changes/lacosamide-adroiq-epar-product-information-tracked-changes_it.docx)

latviešu valoda (LV) (142.91 KB - DOCX)

**First published:**

25/09/2025

[View](/lv/documents/product-information-tracked-changes/lacosamide-adroiq-epar-product-information-tracked-changes_lv.docx)

lietuvių kalba (LT) (152.67 KB - DOCX)

**First published:**

25/09/2025

[View](/lt/documents/product-information-tracked-changes/lacosamide-adroiq-epar-product-information-tracked-changes_lt.docx)

magyar (HU) (145.56 KB - DOCX)

**First published:**

25/09/2025

[View](/hu/documents/product-information-tracked-changes/lacosamide-adroiq-epar-product-information-tracked-changes_hu.docx)

Malti (MT) (145.52 KB - DOCX)

**First published:**

25/09/2025

[View](/mt/documents/product-information-tracked-changes/lacosamide-adroiq-epar-product-information-tracked-changes_mt.docx)

Nederlands (NL) (132.64 KB - DOCX)

**First published:**

25/09/2025

[View](/nl/documents/product-information-tracked-changes/lacosamide-adroiq-epar-product-information-tracked-changes_nl.docx)

norsk (NO) (160.62 KB - DOCX)

**First published:**

25/09/2025

[View](/no/documents/product-information-tracked-changes/lacosamide-adroiq-epar-product-information-tracked-changes_no.docx)

polski (PL) (150.58 KB - DOCX)

**First published:**

25/09/2025

[View](/pl/documents/product-information-tracked-changes/lacosamide-adroiq-epar-product-information-tracked-changes_pl.docx)

português (PT) (118.21 KB - DOCX)

**First published:**

25/09/2025

[View](/pt/documents/product-information-tracked-changes/lacosamide-adroiq-epar-product-information-tracked-changes_pt.docx)

română (RO) (230.12 KB - DOCX)

**First published:**

25/09/2025

[View](/ro/documents/product-information-tracked-changes/lacosamide-adroiq-epar-product-information-tracked-changes_ro.docx)

slovenčina (SK) (147.42 KB - DOCX)

**First published:**

25/09/2025

[View](/sk/documents/product-information-tracked-changes/lacosamide-adroiq-epar-product-information-tracked-changes_sk.docx)

slovenščina (SL) (139.31 KB - DOCX)

**First published:**

25/09/2025

[View](/sl/documents/product-information-tracked-changes/lacosamide-adroiq-epar-product-information-tracked-changes_sl.docx)

Suomi (FI) (121.25 KB - DOCX)

**First published:**

25/09/2025

[View](/fi/documents/product-information-tracked-changes/lacosamide-adroiq-epar-product-information-tracked-changes_fi.docx)

svenska (SV) (134.77 KB - DOCX)

**First published:**

25/09/2025

[View](/sv/documents/product-information-tracked-changes/lacosamide-adroiq-epar-product-information-tracked-changes_sv.docx)

**This page was last updated on** 25/09/2025

## Share this page

[Back to top](#main-content)